234 related articles for article (PubMed ID: 17888585)
1. Diagnostic utility of serum or cerebrospinal fluid levels of toxic advanced glycation end-products (TAGE) in early detection of Alzheimer's disease.
Takeuchi M; Sato T; Takino J; Kobayashi Y; Furuno S; Kikuchi S; Yamagishi S
Med Hypotheses; 2007; 69(6):1358-66. PubMed ID: 17888585
[TBL] [Abstract][Full Text] [Related]
2. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
[TBL] [Abstract][Full Text] [Related]
3. Is pigment epithelium-derived factor level in cerebrospinal fluid a promising biomarker for early diagnosis of Alzheimer's disease?
Yamagishi S; Inagaki Y; Takeuchi M; Sasaki N
Med Hypotheses; 2004; 63(1):115-7. PubMed ID: 15193361
[TBL] [Abstract][Full Text] [Related]
4. Involvement of toxic AGEs (TAGE) in the pathogenesis of diabetic vascular complications and Alzheimer's disease.
Takeuchi M; Yamagishi S
J Alzheimers Dis; 2009; 16(4):845-58. PubMed ID: 19387117
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of human brain suggests pathological synergism of Alzheimer's disease and diabetes mellitus.
Valente T; Gella A; Fernàndez-Busquets X; Unzeta M; Durany N
Neurobiol Dis; 2010 Jan; 37(1):67-76. PubMed ID: 19778613
[TBL] [Abstract][Full Text] [Related]
6. Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease.
Srikanth V; Maczurek A; Phan T; Steele M; Westcott B; Juskiw D; Münch G
Neurobiol Aging; 2011 May; 32(5):763-77. PubMed ID: 19464758
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
8. Possible involvement of advanced glycation end-products (AGEs) in the pathogenesis of Alzheimer's disease.
Takeuchi M; Yamagishi S
Curr Pharm Des; 2008; 14(10):973-8. PubMed ID: 18473848
[TBL] [Abstract][Full Text] [Related]
9. Glyceraldehyde-derived advanced glycation end products in Alzheimer's disease.
Choei H; Sasaki N; Takeuchi M; Yoshida T; Ukai W; Yamagishi S; Kikuchi S; Saito T
Acta Neuropathol; 2004 Sep; 108(3):189-93. PubMed ID: 15221334
[TBL] [Abstract][Full Text] [Related]
10. RAGE, LRP-1, and amyloid-beta protein in Alzheimer's disease.
Donahue JE; Flaherty SL; Johanson CE; Duncan JA; Silverberg GD; Miller MC; Tavares R; Yang W; Wu Q; Sabo E; Hovanesian V; Stopa EG
Acta Neuropathol; 2006 Oct; 112(4):405-15. PubMed ID: 16865397
[TBL] [Abstract][Full Text] [Related]
11. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
12. N epsilon-carboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease.
Gironès X; Guimerà A; Cruz-Sánchez CZ; Ortega A; Sasaki N; Makita Z; Lafuente JV; Kalaria R; Cruz-Sánchez FF
Free Radic Biol Med; 2004 May; 36(10):1241-7. PubMed ID: 15110389
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers of Alzheimer's disease in body fluids.
Zheng Y; He J; Hong T
Sci China Life Sci; 2010 Apr; 53(4):490-6. PubMed ID: 20596916
[TBL] [Abstract][Full Text] [Related]
14. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end products enhance amyloid precursor protein expression by inducing reactive oxygen species.
Ko SY; Lin YP; Lin YS; Chang SS
Free Radic Biol Med; 2010 Aug; 49(3):474-80. PubMed ID: 20471471
[TBL] [Abstract][Full Text] [Related]
16. The relationship between Alzheimer's disease and diabetes: Type 3 diabetes?
Kroner Z
Altern Med Rev; 2009 Dec; 14(4):373-9. PubMed ID: 20030463
[TBL] [Abstract][Full Text] [Related]
17. Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis.
Suzuki T; Araki Y; Yamamoto T; Nakaya T
J Biochem; 2006 Jun; 139(6):949-55. PubMed ID: 16788045
[TBL] [Abstract][Full Text] [Related]
18. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
19. Oxidative stress in Alzheimer's disease hippocampus: a topographical study.
Cruz-Sánchez FF; Gironès X; Ortega A; Alameda F; Lafuente JV
J Neurol Sci; 2010 Dec; 299(1-2):163-7. PubMed ID: 20863531
[TBL] [Abstract][Full Text] [Related]
20. Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease.
Verwey NA; Schuitemaker A; van der Flier WM; Mulder SD; Mulder C; Hack CE; Scheltens P; Blankenstein MA; Veerhuis R
Dement Geriatr Cogn Disord; 2008; 26(6):522-7. PubMed ID: 19052452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
